Quarterly Results of Operations (Unaudited)

12 Months Ended

Jun. 30, 2017

Quarterly Results of Operations (Unaudited) [Abstract]

Quarterly Results of Operations

18.     Quarterly Results of Operations (Unaudited)

The following table present summarized unaudited quarterly financial data:

	Three Months Ended
	June 30,		March 31,		December 31,		September 30,
	2017		2017		2016		2016
	(In thousands, except for per share amounts)
Consolidated Statements of Comprehensive Loss Data:
Revenues	$	642	$	1,323	$	384	$	742
Net loss attributable to Immunomedics, Inc. stockholders		(53,255)		(59,306)		(24,447)		(16,198)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)	$	(0.48)	$	(0.56)	$	(0.25)	$	(0.18)
Weighted average shares used to calculate loss per common share – (basic and diluted)		109,891		107,840		104,657		95,884

	Three Months Ended
	June 30,		March 31,		December 31,		September 30,
	2016		2016		2015		2015
	(In thousands, except for per share amounts)
Consolidated Statements of Comprehensive Loss Data:
Revenues	$	932	$	899	$	671	$	731
Net loss attributable to Immunomedics, Inc. stockholders		(15,901)		(13,996)		(13,746)		(15,394)
Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted)	$	(0.16)	$	(0.15)	$	(0.15)	$	(0.16)
Weighted average shares used to calculate loss per common share – (basic and diluted)		94,770		94,748		94,665		94,596